Pricing Log in Create free account

bioAffinity Technologies, Inc. (BIAF) vs iSpecimen Inc. (ISPC)

bioAffinity Technologies, Inc. and iSpecimen Inc. are both Diagnostics & Research companies. bioAffinity Technologies, Inc. is the larger, with a market value of $3.3M against $2.0M — 1.6× the size. bioAffinity Technologies, Inc. grew revenue faster over the last twelve months: −23.2% against −92.1%. bioAffinity Technologies, Inc. has the higher net margin (−257.3% vs −2,449.0%) and the lower return on invested capital (−408.7% vs 0.00%). Across the 18 metrics below, bioAffinity Technologies, Inc. leads on 11 and iSpecimen Inc. on 7.

Valuation

Metric BIAF ISPC Diagnostics & Research median
P/E n/m n/m 34.52
P/S 0.16 2.39 4.24
P/B 0.25 0.64 3.42
Price to free cash flow n/m n/m 33.51
EV/EBITDA 0.08 0.08 23.44
EV/Sales (0.16) (1.47) 5.18
Earnings yield (3,812.50%) (6,581.25%) (1.50%)
Free cash flow yield (1,223.67%) (973.26%) 0.00%

Profitability

Metric BIAF ISPC Diagnostics & Research median
Gross margin 34.61% (108.26%) 48.32%
Operating margin (209.82%) (2,020.05%) (5.68%)
Net margin (257.33%) (2,449.02%) (4.10%)
Free cash flow margin (195.90%) (1,866.61%) 0.00%
Return on equity (1,860.15%) (968.44%) 0.00%
Return on assets (245.51%) (170.09%) (6.05%)
Return on invested capital (408.67%) 0.00% 0.00%

Growth

Metric BIAF ISPC Diagnostics & Research median
Revenue growth (TTM) (23.18%) (92.11%) 8.99%
EPS growth (last fiscal year) 61.55% 87.03% 20.36%
Revenue growth, 5-year CAGR — (25.10%) 7.30%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BIAF ISPC Diagnostics & Research median
Debt to equity 0.15 0.00 0.01
Current ratio 1.44 0.82 2.27
Net debt to EBITDA 0.57 0.95 0.68

Dividend

Metric BIAF ISPC Diagnostics & Research median
Dividend yield — — 0.67%
Payout ratio — — 0.20

Size

Metric BIAF ISPC Diagnostics & Research median
Market cap 3.34m 2.03m 2.22b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack